Lantheus Holdings logo
Lantheus Holdings LNTH
$ 93.52 -3.26%

Quarterly report 2026-Q1
added 05-07-2026

report update icon

Lantheus Holdings Income Statement 2011-2026 | LNTH

Annual Income Statement Lantheus Holdings

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

5.12 B 6.47 B 4.42 B 4.81 B 3.23 B 1.01 B 699 M 635 M 887 M 282 M 53 M - - - -

Shares

67.5 M 69.2 M 68.3 M 68.5 M 67.5 M 54.1 M 39 M 38.2 M 37.3 M 32 M 24.4 M - - - -

Historical Prices

75.9 93.4 64.7 70.3 47.8 18.7 15.6 22.9 15.3 12.8 2.12 - - - -

Net Income

234 M 312 M 327 M 28.1 M -71.3 M -13.5 M 31.7 M 40.5 M 123 M 26.8 M -14.7 M -3.56 M -61.6 M -42 M -137 M

Revenue

1.54 B 1.53 B 1.3 B 935 M 425 M 339 M 347 M 343 M 331 M 302 M 293 M 302 M 284 M 288 M 356 M

Cost of Revenue

600 M 546 M 587 M 353 M 238 M 201 M 173 M 168 M 169 M 164 M - - - - -

Gross Profit

942 M 988 M 710 M 582 M 188 M 139 M 175 M 175 M 162 M 138 M 136 M 126 M 77.4 M 75.2 M 95.2 M

Operating Income

311 M 457 M 365 M 36.2 M -60.8 M -4.2 M 51.7 M 64.5 M 51.9 M 56.6 M 42.5 M 39.4 M -18.9 M - -

Interest Expense

31.3 M 37.2 M 20 M 7.18 M 7.75 M 9.48 M 13.6 M 17.4 M 18.4 M 26.6 M 38.7 M 42.3 M 42.9 M - -

EBITDA

381 M 522 M 425 M 84.1 M -18.5 M 20.5 M 65 M 78.4 M 71.1 M 68.5 M 62.2 M 57.7 M 3.79 M -7.96 M 15.5 M

Operating Expenses

- - - - - - 123 M 110 M 110 M 87.6 M 93 M 86.1 M 98.7 M 111 M 112 M

General and Administrative Expenses

275 M 194 M 125 M 134 M 150 M 69.3 M 61.2 M 50.2 M 49.8 M 38.8 M 43.9 M 37.3 M 33 M 32.5 M 32.9 M

All numbers in USD currency

Quarterly Income Statement Lantheus Holdings

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

64.7 M 67.2 M 68.5 M 68.7 M 70.9 M 69.5 M 69.4 M 68.8 M 69.9 M 68.4 M 68.4 M 67.7 M 68.9 M 68.8 M 68.7 M 68 M 67.7 M 67.6 M 67.5 M 67.1 M 66.9 M 66.8 M 43.1 M 39.4 M 39.3 M 39.1 M 39 M 38.6 M 39.3 M 38.3 M 38.2 M 37.9 M 38.5 M 37.4 M 37.2 M 36.9 M 38.5 M 31.2 M 30.4 M 30.4 M 30.4 M 30.4 M 18.9 M 18.1 M 18.1 M 18.1 M 18.1 M - - - - - - - - - - - - -

Net Income

118 M 27.8 M 78.8 M 72.9 M - 131 M 62.1 M 131 M - 132 M 94.1 M -2.81 M - 61.2 M 43.1 M 43 M - -13.4 M -26.7 M 9.01 M - -6.39 M -7.01 M 3.34 M 10.4 M 4.86 M 6.41 M 9.95 M 13.3 M 9.27 M 9.74 M 8.21 M 97.1 M 8.53 M 13.6 M 4.14 M 4.87 M 4.22 M 7.35 M 10.3 M 3.92 M 5.39 M -24.4 M 375 K 227 K -867 K -1.64 M -1.28 M - - - - - - - - - - - -

Revenue

377 M 384 M 378 M 373 M - 379 M 394 M 370 M - 320 M 322 M 301 M - 239 M 224 M 209 M - 102 M 101 M 92.5 M - 88.5 M 66 M 90.7 M 89.3 M 85.8 M 85.7 M 86.5 M 86.3 M 88.9 M 85.6 M 82.6 M 81.2 M 79.9 M 88.8 M 81.4 M 74.4 M 73.1 M 78 M 76.5 M 71.2 M 74.1 M 73.3 M 74.8 M 77 M 75.7 M 75.6 M 73.3 M - - - - - - - - - - - -

Cost of Revenue

146 M 162 M 137 M 135 M - 137 M 138 M 128 M - 120 M 119 M 224 M - 91.9 M 85.7 M 79.8 M - 59.4 M 55 M 51.5 M - 52.3 M 40.2 M 52.7 M - 44.2 M 41.1 M 42.4 M - 44 M 41.7 M 40.3 M - 41.4 M 42.9 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

231 M 222 M 241 M 238 M - 242 M 256 M 242 M - 200 M 203 M 77.1 M - 147 M 138 M 129 M - 42.7 M 46.1 M 41 M - 36.3 M 25.8 M 38 M 44.6 M 41.6 M 44.6 M 44.1 M 43.8 M 44.9 M 43.8 M 42.3 M 37.9 M 38.5 M 45.9 M 39.8 M 34.6 M 33.7 M 35.8 M 33.7 M 33.4 M 33.7 M 32.7 M 35.8 M 32.8 M 31.6 M 31.1 M 30.1 M - - - - - - - - - - - -

Operating Income

81.3 M 43.6 M 88 M 102 M - 134 M 103 M 107 M - 112 M 124 M -9.34 M - 85.7 M 63.2 M 58.9 M - -14.3 M -26.8 M 15.6 M - -5.25 M -5.54 M 7.12 M - 8.52 M 14.5 M 16.2 M - 16.5 M 15.9 M 15.1 M - 12.8 M 17.9 M 11.9 M - 12.6 M 14.2 M 17.7 M - 13.4 M 5.36 M 11.4 M - 9.22 M 9.98 M - - - - - - - - - - - - -

Interest Expense

5.71 M 2.56 M 6.9 M 14.1 M - 9.95 M 9.04 M 8.79 M - 52.6 M 4.48 M 4.99 M - 1.63 M 1.47 M 1.51 M - 1.57 M 1.94 M 2.72 M - 2.81 M 1.91 M 1.95 M - 2.36 M 4.54 M 4.59 M - 4.45 M 4.3 M 4.05 M - 4.44 M 4.28 M 5.42 M - 6.79 M 6.98 M 7.02 M - 7.1 M 13.9 M -383 K - 441 K 10.6 M - - - - - - - - - - - - -

EBITDA

104 M 58.2 M 96 M 116 M - 146 M 113 M 122 M - 124 M 137 M 5.27 M - 89.6 M 66.5 M 70.7 M - 15.8 M -23.6 M 23.7 M - 11 M 2.22 M 10.9 M - 18.4 M 21.1 M 19.5 M - 27 M 23 M 18.7 M - 27.8 M 29.2 M 18.1 M - 25.3 M 22.6 M 21.8 M - 30.1 M 17.9 M 19.5 M - 24 M 19.9 M - - - - - - - - - - - - -

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 21.9 M - 20.3 M 27.3 M 24.4 M - 22.4 M 21.1 M - - - - - - - - - - - - -

General and Administrative Expenses

57.5 M 81.9 M 66.5 M 56.8 M - 40.5 M 47.4 M 47.9 M - 35.7 M 26.2 M 23.3 M - 23.8 M 32.6 M 37.6 M - 28.6 M 43.2 M 16.1 M - 18.2 M 20.7 M 16.7 M - 18.1 M 13.3 M 12.6 M - 13.6 M 11.6 M 12.5 M - 12.1 M 11.2 M 12.3 M - 10.1 M 9.24 M 9.51 M - 9.21 M 15.4 M 9.12 M - 11 M 8.99 M - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Lantheus Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Co-Diagnostics Co-Diagnostics
CODX
$ 1.29 -20.86 % $ 1.72 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 111.67 -1.39 % $ 33.9 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 19.22 1.8 % $ 557 M usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Fulgent Genetics Fulgent Genetics
FLGT
$ 15.84 -2.16 % $ 479 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Illumina Illumina
ILMN
$ 141.26 -1.38 % $ 22.5 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.8 - $ 7.96 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 19.81 -3.34 % $ 1.06 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 417.74 -0.34 % $ 12.1 B usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 039.9 -0.19 % $ 21.4 B schweizSchweiz
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Myriad Genetics Myriad Genetics
MYGN
$ 3.61 -0.41 % $ 334 M usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
NeoGenomics NeoGenomics
NEO
$ 8.28 -0.96 % $ 1.06 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
National Research Corporation National Research Corporation
NRC
$ 18.7 -1.22 % $ 419 M usaUSA
Natera Natera
NTRA
$ 188.14 -4.45 % $ 18.5 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 154.29 -3.04 % $ 7.65 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 25.27 -0.9 % $ 24 B niderlandNiderland
Guardant Health Guardant Health
GH
$ 94.56 -4.16 % $ 11.9 B usaUSA
Personalis Personalis
PSNL
$ 6.45 -3.95 % $ 576 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 117.67 0.5 % $ 9.71 B irlandaIrlanda
Senseonics Holdings Senseonics Holdings
SENS
$ 5.7 -2.06 % $ 238 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
$ 52.99 - $ 2.69 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Biomerica Biomerica
BMRA
$ 2.36 -2.07 % $ 5.42 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 251.95 -0.81 % $ 21 B usaUSA
Thermo Fisher Scientific Thermo Fisher Scientific
TMO
$ 439.75 -1.87 % $ 166 B usaUSA
Trinity Biotech plc Trinity Biotech plc
TRIB
$ 0.57 -1.7 % $ 205 M irlandaIrlanda
Celcuity Celcuity
CELC
$ 134.2 -0.39 % $ 6.27 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Twist Bioscience Corporation Twist Bioscience Corporation
TWST
$ 48.67 -8.08 % $ 2.91 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 8.22 -2.49 % $ 1.78 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 187.17 -0.41 % $ 20.8 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA